Unknown

Dataset Information

0

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.


ABSTRACT: Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete response (CR) rates and may improve overall survival (OS) for patients with

SUBMITTER: Landau H 

PROVIDER: S-EPMC5220129 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.

Landau H H   Smith M M   Landry C C   Chou J F JF   Devlin S M SM   Hassoun H H   Bello C C   Giralt S S   Comenzo R L RL  

Leukemia 20160818 1


Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete response (CR) rates and may improve overall survival (OS) for patients with <CR. We retrospectively analyzed outcomes for 143 patients who underwent RA-SCT with or without consolidation. Melphalan was  ...[more]

Similar Datasets

| S-EPMC9242830 | biostudies-literature
| S-EPMC5927852 | biostudies-literature
| S-EPMC6202992 | biostudies-literature
| S-EPMC2200859 | biostudies-literature
| S-EPMC4930380 | biostudies-literature
| S-EPMC5841939 | biostudies-literature
| S-EPMC7787969 | biostudies-literature
| S-EPMC6815750 | biostudies-literature
| S-EPMC3640126 | biostudies-literature